-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind Medicine Completes Patient Enrollment For Part C Of Ongoing Phase I/IIa Clinical Trial Evaluating CMND-100

Benzinga·11/16/2026 12:40:09

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder ("AUD"), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.

The completion of patient enrollment for Part C marks another important milestone in Clearmind’s clinical development program and reflects the continued strong execution of its Phase I/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability data from Part A in healthy volunteers.

Part C is a randomized, double-blind, placebo-controlled multiple-dose study designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100. The trial is being conducted at premier clinical research sites across the United States and Israel, including Johns Hopkins University School of Medicine, Yale School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.